Fundamentals First ETF(KNOW.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Fundamentals First ETF
KNOW.US
News
View More

FDA Grants Breakthrough Therapy Designation to Novartis Ianalumab for Sjögren’s Disease

Novartis AG has received Breakthrough Therapy designation from the FDA for ianalumab, aimed at treating Sjögren’s disease. This designation is based on phase III trial results indicating its potential to meet significant unmet medical needs. Novartis plans to seek global regulatory approval for ianalumab starting in early 2026, which could make it the first targeted treatment for this autoimmune condition.

Reuters·
US
NVS
+0.83%
DE
NOT
0.00%
Reuters·
US
NVS
+0.83%
DE
NOT
0.00%

BUZZ-Bernstein launches coverage on KLA with 'outperform'

Bernstein has initiated coverage on KLA Corpwith an 'outperform' rating and a price target of $1,700, indicating an approximate 18% upside from the stock's last close. The brokerage highlights KLA's leading position in the Process Control segment of semiconductor manufacturing, with over 57% market share. They expect continued share gains due to KLA's strong competitive position and favorable growth mix. KLA's outlook for CY26 has already accounted for normalization in China, reducing risks associated with its China exposure. Currently, 16 out of 30 brokerages recommend a 'buy' or higher rating for KLA.

Reuters·
US
KLAC
+1.48%
Reuters·
US
KLAC
+1.48%

Sandoz confirms European Commission approval of Ondibta, expects launch by early 2027

Sandoz confirms European Commission approval of Ondibta, expects launch by early 2027

marketscreener·
US
NVS
+0.83%
marketscreener·
US
NVS
+0.83%

Ashton Thomas Securities LLC Acquires New Shares in Novartis AG $NVS

Ashton Thomas Securities LLC acquired 34,439 shares of Novartis AG (NYSE:NVS) valued at approximately $4.4 million during Q3. Other institutional investors also increased their stakes, with Keybank National Association raising its holdings by 13.2%. Novartis reported Q3 earnings of $2.25 EPS, slightly missing estimates, but revenue rose to $14.36 billion. Analysts have mixed ratings on Novartis, with an average rating of "Hold" and a consensus target price of $119.75. The company focuses on innovative pharmaceuticals across various therapeutic areas.

Market Beat·
DE
NOT
0.00%
US
NVS
+0.83%
Market Beat·
DE
NOT
0.00%
US
NVS
+0.83%

JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals

At the J.P. Morgan Healthcare Conference 2026, Novartis announced its strategy to enhance its neuroscience portfolio through mergers, acquisitions, and licensing deals. The $12bn acquisition of Avidity Biosciences is set to close in H1 2026, adding significant assets to its neuromuscular portfolio. Additionally, a licensing agreement with SciNeuro for an Alzheimer’s treatment was revealed, alongside a collaboration with Arrowhead for a Parkinson’s therapy. Novartis aims to strengthen its pipeline in neuromuscular and neurodegenerative diseases, positioning neuroscience as a key revenue driver.

Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%
Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%
© 2026 Longbridge｜Disclaimer